Program
대한상공회의소 국제회의실(쇼케이스), 소회의실(1:1 파트너링)
| Time | Program | |||
|---|---|---|---|---|
| 09:30 ~ 10:00 |
Registration |
|||
| 10:00 ~ 10:20 |
Welcome address
|
|||
| 10:20 ~ 10:50 |
Showcase 1 - Innovation at Weill Cornell Medicine Overview and Licensing Opportunities
|
- | Poster Exhibition |
|
| 10:50 ~ 11:20 |
Showcase 2 - Introduction to Innovation at Dana-Farber
|
- | ||
| 11:20 ~ 11:50 |
Showcase 3 - Duke NUS Medical School-Research in Singapore for Asia and the World
|
- | ||
| 11:50 ~ 12:50 |
Lunch |
- | ||
| 12:50 ~ 13:20 | - | |||
| 13:20 ~ 13:50 | - | |||
| 13:50 ~ 14:00 |
Break |
|||
| 14:00 ~ 14:20 | Partnering meeting 1~4 | |||
| 14:20 ~ 14:40 | ||||
| 14:40 ~ 15:00 | ||||
| 15:00 ~ 15:20 |
Showcase 9 - Chimeric Antigen Receptor (CAR)-T cells Targeting IL-13Ra2 Positive Human Solid Cancers 🎥Bharatkumar H Joshi, MD. FDA Technology Transfer
|
|||
| 15:20 ~ 15:40 |
Break |
|||
| 15:40 ~ 17:00 |
- |
Partnering meeting 5~8 | ||
Showcase 1 : Weill Cornell Medical College
Combining the full power of business development expertise with the rich history of Weill Cornell Medicine and the breadth of Cornell University, Weill Cornell Medicine Enterprise Innovation provides a bridge between academic researchers and industry stakeholders. Weill Cornell Medicine Enterprise Innovation integrates Weill Cornell’s Center for Technology Licensing (CTL), Office of BioPharma Alliances and Research Collaborations, BioVenture eLab, and Daedalus Fund for Innovation under a single, united organization and encompasses the entire spectrum of an effective innovation ecosystem. Our team works collaboratively with a network of partners to commercialize technology across major pillars of biomedical innovation including therapeutics, devices, diagnostics and precision medicine, tangible properties, digital health, and data assets. By translating groundbreaking research at Weill Cornell Medicine into revolutionary care through commercial partnerships, lifechanging diagnostics, treatments and healthcare solutions reach patients faster than ever before.
Showcase 2 : Dana-Farber
Showcase 3 : Duke-NUS Medical School
Renowned as a research powerhouse, Duke-NUS is at the forefront of cutting-edge research in critical public health areas in Singapore. Our distinguished scientists are advancing the understanding, diagnosis, and treatment of diseases, with far-reaching implications that benefit patients worldwide. Our five Signature Research Programmes (SRPs) form the core of our research efforts, addressing major health challenges in Singapore. Notably, our team was the first Asian recipient of the American Association for Cancer Research (AACR) Team Science Award, acknowledging their significant impact on cancer research.
Our strategic partnership with Singapore Health Services (SingHealth), including the renowned Singapore General Hospital, strengthens our capabilities. Together, through the SingHealth Duke-NUS Academic Medical Centre, we develop exceptional clinical education and foster cutting-edge research that translates scientific findings into tangible healthcare improvements.
Together, we are shaping the future of medicine and positively impacting millions of lives.
Focus Areas: Cardiovascular and Metabolic Diseases, Infectious Diseases, Neurological and Psychiatric disorders, Cancer and Stem Cell diseases.
Showcase 4 : Ramot At Tel Aviv University
To foster, initiate, lead and manage the transfer of new technologies, from the laboratory to the marketplace.
We strive to strengthen the bond between industry and the Tel Aviv University research community in the following ways:
· Secure strong patent protection for TAU inventions
· Maximize the commercial potential of technologies developed at TAU
· Increase the transfer rate of emerging technologies from lab to industry
· Generate new revenue streams for TAU inventors by licensing TAU technologies
· Initiate and support the establishment of companies based on promising TAU technologies
· Support technological entrepreneurship at TAU
Showcase 5 : Cancer Research Horizons
By uniting our commercial partnerships and therapeutic innovation capabilities, Cancer Research Horizons is uniquely placed to support translational funding, licensing and collaboration, spin-out creation, and offer a full spectrum of drug discovery and clinical capabilities. With access to Cancer Research UK’s network of 4,000 exceptional researchers, and £300+ million of annual research spend, we’re a powerful partner in the fight to conquer cancer. Every penny we make goes back into funding the next bold steps, to help bring forward the day when all cancers are conquered. To date, we’ve played an instrumental role in forming over 60 spin-out companies and helped to bring 11 cancer drugs to market.
Showcase 6 : Cambridge Enterprise Ltd
We do this by helping innovators, experts and entrepreneurs use commercial avenues to develop their ideas and expertise for the benefit of society, the economy, themselves, and the University.
Liaising with organisations both locally and globally, we offer expert advice and support in commercialisation and social enterprise, including help with academic consultancy services; the protection, development, and licensing of ideas; new company and social enterprise creation, and seed funding.
Showcase 7 : Stanford SPARK Program
Building upon Stanford’s tradition of technological innovation and entrepreneurship, Chemical and Systems Biology Professor, Daria Mochly-Rosen, founded the SPARK program to provide a cost-effective model to generate proof of concept using out-of-the-box academic approaches combined with industry standards.
SPARK provides access to specialized knowledge and technical expertise regarding drug and diagnostic development, dedicated core laboratory facilities, and sources of funding to support translational efforts.
SPARK IS BASED ON FIVE PRINCIPLES:
1. Multiple opinions
2. No need to reach consensus
3. Open exchange and no hierarchy
4. On University campus
5. Ongoing, two-year program
SPARK at Stanford includes graduate level courses about the drug development process as well as a program for “SPARK Scholars”, which provides funding for their product proposals and mentoring for participants. Mentoring is provided by multiple advisors from the same field with expertise in product development, clinical care, and business, preparing participants for careers that link investigation with important new therapies.
Product proposals are reviewed annually by an expert panel of faculty and industry advisors. The panel reviews new, unlicensed disclosures made to the University Office of Technology Licensing as well as proposals submitted from across the university. SPARK Scholars (AKA “SPARKees”) are funded for an average of two years and participate in weekly seminars with industry and academic experts.
In summary, SPARK has achieved unprecedented success in translating early academic discoveries to solutions addressing unmet needs. Moreover, the program has educated hundreds of faculty members, postdocs and students on the translational process. The majority of SPARK projects address the neglected areas of child and maternal health, global health, and orphan diseases. Moreover, the SPARK model has been adopted now in over 60 academic institutions throughout the world (in over 20 countries on six continents).
Showcase 8 : University of Toronto
With this stimulating environment to draw upon, it is no surprise that the University of Toronto is widely recognized as one of the world’s great institutions of higher learning. Respected university rankings have placed UofT consistently among the world’s top research institutions over the past several years. It is consistently ranked in the Top 5 in the world for ‘research output.’ With its nine hospital partners, UofT forms a powerhouse ranked 3rd in the world for both clinical medicine (NTU Ranking 2020) and healthcare (Nature Index 2023).
UofT and its partner hospitals form a medical partnership of global proportions. Researchers at UofT collaborate with researchers and clinicians in our many affiliated hospitals. Many of these hospitals are literally “just down the street” from our campus. Collectively, UofT and our partner hospitals conduct over $1.5B in research each year. Some of its best known discoveries and inventions include insulin (1921), the cardiac pacemaker (1940s), stem cells (1961) and the first nerve transplant (1988).
Over the past ten years, U of T researchers and partner hospitals filed more than one thousand patent applications – that's one patent application filed every three days and protecting hundreds of new ideas. Over the last decade, entrepreneurship has played an increasingly significant role in assisting UofT students and faculty choose their own path in bringing UofT inventions to market. Entrepreneurs have created > 600 start-ups, raising > $2.5B in venture funding over the past 10 years.
Showcase 9 : FDA Technology Transfer
To make collaborations and scientific exchanges possible, FDA's Technology Transfer Program uses various agreement mechanisms, including:
- Cooperative Research and Development Agreements (CRADAs)
- Material Transfer Agreements (MTAs), and
- Confidential Disclosure Agreements (CDAs)
The Technology Transfer program also helps FDA inventors report new technologies, which are then considered for patent application filing. We carry out patenting and licensing of FDA technologies when these activities support FDA’s public health mission.
Speaker : Iris Bica - Business Development & Licensing Associate
-
Biography
Iris Bica is a Business Development and Licensing Associate at the Center for Technology Licensing at Weill Cornell Medicine (CTL@WCM). In this role, she is responsible for partnering and outreach efforts to match WCM innovations with the right development partners. Iris works to promote participation in the Weill Cornell innovation ecosystem by engaging industry and venture groups through direct outreach, maintaining databases of available technologies, and attending key industry conferences.
Iris has a passion for connecting innovative researchers with partners with the resources and capabilities to accelerate development of their projects. Before joining the CTL@WCM in 2022, Iris gained experience in business development and licensing at CancerTools.org, the tangible materials arm of Cancer Research UK. In this role, she managed in-licensing of tangible materials from universities and research institutes in order to make academic research tools available to the global research community.
Speaker : Emy Chen - Vice President of Innovation
-
Biography
Emy Chen, PhD, is Vice President of Innovation at Dana-Farber Cancer Institute within the Robert and Renée Belfer Office for Dana-Farber Innovations (BODFI). In this role, she has oversight over the Innovations Licensing, Research Contracts, Compliance and Finance teams. A primary focus for her role is to continuously refine and optimize the Innovation team’s ability to provide excellent partnership and collaboration with clinicians and research scientists at Dana-Farber and to catalyze and sustain relationships with external stakeholders in industry in order to bring new discoveries from the labs at Dana-Farber to patients. Prior to joining Dana-Farber, Emy was Director of Licensing at MassGeneral Brigham Innovation, where she spent 13 years supporting investigators and building relationships with biotech and pharma companies, primarily for innovators in the disciplines of medicine, neuroscience and dermatology. Emy holds a PhD from Harvard University in Molecular and Cellular Biology, a BA from University of California, Berkeley in Molecular and Cell Biology, and is a registered patent agent with the United States Patent and Trademark Office (USPTO).
Speaker : Tarunkumar Maheshwari - Head of Business Development
-
Biography
Dr Tarun Maheshwari is an experienced life science and healthcare executive with a well-rounded and a track record of managing wide spectrum of activities business development, external innovation, alliance management, negotiations with substantial experience in establishing public-private partnerships having negotiated multi-million-dollar collaboration frameworks and license deals.
He has over 20 years of experience in the biomedical sector that spans the entire value chain: clinical practice, training, and education, clinical development, research, and commercialization. He passionate about technology, innovation, entrepreneurship and how these can combine to make real positive changes in medicine.
He has set up and currently directs the business development and ecosystem development unit at Duke NUS medical school, The office positions the innovations and capabilities of Duke NUS researchers and investigators to industry in order to develop new commercial relationships, diversify the commercialization portfolio, and increase asset commercialization across five signature disease/therapy areas.
Speaker : Tali Aloya, PhD - VP, Business Development, Life Sciences
-
Biography
Dr. Aloya brings over 20 years of profound managerial and technological experience in the bio-pharmaceutical industry. Before joining Ramot, Dr. Tali Aloya served as CEO at BioRap Technologies as well as business development director at T3, Technion Tech Transfer unit. Formerly, she was the CEO and IP director at High Jump Pharma Ltd.
Prior to that, Tali functioned as CTO & IP manager at Pelixcure company, part of Radbiomed accelerator Tali also served as CTO, and IP manager for Pharmaceutical and biotech projects at Radbiomed accelerator in addition to scouting for projects from academia and hospitals. Before RAD Biomed, she was Project manager at Neurim pharmaceuticals.
Dr. Aloya also served as IP Manager at The Technology Transfer Company of Chaim Sheba Medical Center Tel Hashomer.
Earlier in her career Dr. Aloya served as a scientist and project manager for 10 years at Aposense, a company in the field of cancer diagnostics.
Dr. Aloya holds a PhD in Biological Chemistry, from The Hebrew University of Jerusalem where she received the "Mifal-Hapais Landau" award for distinguished Ph.D student. She completed a Post-doctoral fellowship at the Weizmann Institute of Science.
Speaker : Keemia Azvine - Business Development Manager (Therapeutics)
-
Biography
Keemia Azvine is a Business Development Manager at Cancer Research Horizons, where she develops and commercializes novel research findings arising from CRUK-funded research through partnership with the life sciences industry. She has experience commercializing a broad range of technologies across diagnostics, data and therapeutics, now with a particular focus on translating exciting therapeutic innovations. Prior to her role in Business Development at Cancer Research Horizons, Keemia led multiple strategic projects across Cancer Research UK’s Research & Innovation directorate, including within Strategic Alliances and Corporate Strategy.
Prior to joining CRUK, Keemia studied Natural Sciences with Management at University of Cambridge, specializing in Neuroscience, Psychology and Behaviour.
Keemia sits on the Board of Trustees for Cancer Awareness for Teens and Twenties, a UK-based charity ensuring that more young people know about the signs and symptoms of cancer.
Speaker : Ione Meyer, Senior Commercialisation Associate (Life Sciences)
-
Biography
Ione is a Senior Commercialisation Associate in the Life Sciences team providing support for the evaluation of new inventions, protection of IP, developing commercial opportunities and licensing technologies arising from the University.
Prior to joining Cambridge Enterprise, Ione worked as a Grant Scheme Manager at the Royal Society where she managed a portfolio of international grants. She has a PhD from the UCL Institute of Neurology, which has given her experience of working on translational research. She also has a BSc in Biomedical Sciences from the University of Warwick, and an MSc in Neuroscience from UCL.
Speaker : Jeewon Kim, Ph.D, MBA, Associate Director of Business Development
-
Biography
Dr. Jeewon Kim, PhD, MBA, is an Associate Director of Business Development and program manager at SPARK Translational Research Program at Stanford University School of Medicine. She is responsible for strategic alliance management for commercialization of innovative scientific discoveries from SPARK program. Her expertise is in the development of therapeutics and molecular devices in healthcare and wellness industries, interacting with key opinion leaders. Previously worked as a researcher at Daesang pharmaceutical/nutraceutical company (Korea), consultant for startups (Kinemed and OurMemos, in US) and held a managing scientist/group lead position overseeing the entire operation of a pre-clinical lab (Stanford Cancer Institute). Finished post-doctoral fellowship at Stanford, graduated with a PhD from University of California, Berkeley and undergraduate degree from Seoul National University (South Korea). Recently earned an MBA from Boston University working full time to leverage scientific and management skills to further career in business analysis, strategic planning, entrepreneurship and innovation. She published more than 25 research papers and filed for three patents. She is on the advisory board for Bio Investor Forum at BIO.
Speaker : Rohan Alvares, Ph.D, Technology Analyst – Life Sciences
-
Biography
Rohan Alvares, PhD, obtained his doctorate in Chemistry from the University of Toronto. He currently works as a Technology Analyst – Life Sciences also at the University of Toronto where he conducts due diligence on disclosed inventions and is involved in marketing and commercialization of these technologies. He has a keen interest in the early-stage life science environment and in identifying and progressing technologies towards commercialization. He has eight multidisciplinary publications in his academic career and was awarded a Young Investigator Award from the International Society for Magnetic Resonance in Medicine for driving a collaborative project to develop a novel molecular imaging probe.
Speaker : Bharatkumar H Joshi, MD, PhD, Lead Inventor, Chemist, Tumor Vaccines and Biotechnology Branch
-
Biography
I work as a Research-Reviewer Chemist in the Tumor Vaccines and Biotechnology Branch, Division of Cell Therapy II (DCT2), Office of Cellular Therapy & Human Tissues CMC (OCTHT), Office of Therapeutic Products, Center for Biologics Evaluation and Research, U.S. FDA. I am a research-reviewer working on regulatory assignments of investigational new drugs mainly of cancer vaccines and research to have hands on experience on to study translational research focusing on biological attributes of cellular and gene therapy products.
Chemist, Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD (2002-present)
